Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RCKT
stocks logo

RCKT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.435
-29.78%
--
--
-0.444
-20.66%
--
--
-0.310
-47.41%
Estimates Revision
The market is revising Downward the revenue expectations for Rocket Pharmaceuticals, Inc. (RCKT) for FY2025, with the revenue forecasts being adjusted by -96.07% over the past three months. During the same period, the stock price has changed by 4.27%.
Revenue Estimates for FY2025
Revise Downward
down Image
-96.07%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-4.25%
In Past 3 Month
Stock Price
Go Up
up Image
+4.27%
In Past 3 Month
Wall Street analysts forecast RCKT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCKT is 9.83 USD with a low forecast of 7.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast RCKT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCKT is 9.83 USD with a low forecast of 7.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
2 Hold
1 Sell
Moderate Buy
Current: 3.420
sliders
Low
7.00
Averages
9.83
High
16.00
Current: 3.420
sliders
Low
7.00
Averages
9.83
High
16.00
JPMorgan
Neutral -> Underweight
downgrade
2025-11-18
Reason
JPMorgan
Price Target
2025-11-18
downgrade
Neutral -> Underweight
Reason
JPMorgan downgraded Rocket Pharmaceuticals to Underweight from Neutral without a price target. The firm believes Rocket has an "interesting" gene therapy portfolio primarily aimed at rare, genetically driven heart conditions. While the shares as ascribing minimal pipeline credit, the setup is challenging for upside over the next 12 months, the analyst tells investors in a research note. JPMorgan sees risks with Rocket's lead program in Danon disease.
BofA
Buy
downgrade
$10 -> $8
2025-11-18
Reason
BofA
Price Target
$10 -> $8
2025-11-18
downgrade
Buy
Reason
BofA lowered the firm's price target on Rocket Pharmaceuticals to $8 from $10 and keeps a Buy rating on the shares, citing an updated cash position following the company's Q3 update.
Chardan
Buy
maintain
$12
2025-08-20
Reason
Chardan
Price Target
$12
2025-08-20
maintain
Buy
Reason
Chardan keeps a Buy rating on Rocket Pharmaceuticals with a $12 price target after the FDA lifted the clinical hold on company' Phase II trial of RP-A501 in Danon disease. The trial proceeding with a lower dose "sounds reasonable" and does not involve the addition of a new regimen component with an unknown profile in Danon, the analyst tells investors in a research note. Chardan believes the completion date could be late in 2026 with a second half of 2027 readout on the 12-month primary endpoint, consistent with its 2028 launch projections.
BofA
Neutral -> Buy
upgrade
$4 -> $10
2025-08-20
Reason
BofA
Price Target
$4 -> $10
2025-08-20
upgrade
Neutral -> Buy
Reason
BofA upgraded Rocket Pharmaceuticals to Buy from Neutral with a price target of $10, up from $4.
BofA
Neutral -> Buy
upgrade
$4 -> $10
2025-08-20
Reason
BofA
Price Target
$4 -> $10
2025-08-20
upgrade
Neutral -> Buy
Reason
As previously reported, BofA upgraded Rocket Pharmaceuticals to Buy from Neutral with a price target of $10, up from $4, after the FDA lifted the clinical hold on the company's Phase 2 trial of RP-A501 for the treatment of Danon disease. Rocket's restructuring had suggested the process to have the hold lifted would be "lengthy," so today's news is "positive surprise" that removes a key overhang and sets up a path to shares re-rating, the analyst tells investors. Following the update, the firm is increasing its view on the odds of success for 'A501 to 50% from 15%, while maintaining its "more conservative" 2028 launch assumption.
BofA
Buy -> Neutral
downgrade
$9 -> $4
2025-07-25
Reason
BofA
Price Target
$9 -> $4
2025-07-25
downgrade
Buy -> Neutral
Reason
BofA downgraded Rocket Pharmaceuticals to Neutral from Buy with a price target of $4, down from $9. Given the FDA's clinical hold on RP-A501, the decision to reduce expenses and re-prioritize the pipeline makes "financial and strategic sense," the analyst tells investors. However, the firm also views the decision as "tacit acknowledgement that the outlook for the story's primary value driver and anchor asset is likely to remain uncertain near term," the analyst added. The firm thinks investors may be slow to re-engage, leaving shares range-bound in the near term.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Rocket Pharmaceuticals Inc (RCKT.O) is -2.11, compared to its 5-year average forward P/E of -7.65. For a more detailed relative valuation and DCF analysis to assess Rocket Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.65
Current PE
-2.11
Overvalued PE
-2.58
Undervalued PE
-12.72

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.71
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-1.38
Undervalued EV/EBITDA
-12.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
754.45
Current PS
0.00
Overvalued PS
3185.81
Undervalued PS
-1676.90
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

RCKT News & Events

Events Timeline

(ET)
2025-11-06
16:03:15
Rocket Pharmaceuticals announces Q3 earnings per share of 45 cents, below consensus estimate of 52 cents.
select
2025-10-14 (ET)
2025-10-14
07:03:55
Rocket Pharmaceuticals reveals FDA has accepted Kresladi BLA resubmission
select
2025-10-03 (ET)
2025-10-03
10:38:45
Rocket Pharmaceuticals retracts BLA submission for Fanskya
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-02Businesswire
KBRA Assigns Ratings to $499.3 Million RCKT Mortgage Trust 2025-CES12
  • Transaction Size: RCKT Mortgage Trust 2025-CES12 is a $499.3 million RMBS transaction fully sponsored by Rocket Mortgage, LLC and its affiliate Woodward Capital Management LLC, indicating strong market demand for newly originated second lien mortgages.
  • Loan Characteristics: The transaction consists of 5,485 newly originated closed-end second lien mortgages, with an average seasoning of less than one month, reflecting confidence and liquidity in the market for new loans.
  • Interest Rate Structure: The mortgage pool features a diverse interest rate structure with fixed-rate loans of 4.0% for 10-year, 8.3% for 15-year, 65.0% for 20-year, and 22.6% for 30-year terms, catering to various borrower needs and enhancing market appeal.
  • Rating Methodology: KBRA's rating approach involved loan-level analysis through its Residential Asset Loss Model (REALM), incorporating third-party due diligence results and cash flow modeling, ensuring the accuracy and reliability of the ratings, which bolsters market confidence in the transaction.
[object Object]
Preview
2.0
11-18Benzinga
Major Stocks Including Helmerich and Payne, Invivyd, and Home Depot Decline in Tuesday's Pre-Market Trading

  • U.S. Stock Futures: U.S. stock futures are down, with Dow futures dropping approximately 200 points on Tuesday morning.

  • Helmerich and Payne Inc: The company reported a fourth-quarter loss of 1 cent per share despite quarterly sales of $1.012 billion, leading to a 7% drop in its shares during pre-market trading.

  • Other Stocks Declining: Several other stocks, including Alpha Technology Group Ltd and Invivyd Inc, experienced significant declines in pre-market trading, with drops of 19% and 13.4%, respectively.

  • Home Depot's Performance: Home Depot's shares fell 2% after reporting worse-than-expected third-quarter adjusted EPS and lowering its FY25 adjusted EPS outlook.

[object Object]
Preview
9.5
11-07NASDAQ.COM
Rocket Pharmaceuticals, Inc. Reports Smaller Q3 Loss, Surpassing Expectations

  • Quarterly Loss: Rocket Pharmaceuticals reported a third-quarter loss of $50.33 million, or $0.45 per share, an improvement from a loss of $66.72 million, or $0.71 per share, in the same quarter last year.

  • Analyst Expectations: The company's loss per share beat analysts' expectations, which had forecasted a loss of $0.52 per share, excluding special items.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Rocket Pharmaceuticals Inc (RCKT) stock price today?

The current price of RCKT is 3.42 USD — it has increased 2.4 % in the last trading day.

arrow icon

What is Rocket Pharmaceuticals Inc (RCKT)'s business?

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of gene therapies for rare and devastating diseases. The Company has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.

arrow icon

What is the price predicton of RCKT Stock?

Wall Street analysts forecast RCKT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCKT is 9.83 USD with a low forecast of 7.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Rocket Pharmaceuticals Inc (RCKT)'s revenue for the last quarter?

Rocket Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Rocket Pharmaceuticals Inc (RCKT)'s earnings per share (EPS) for the last quarter?

Rocket Pharmaceuticals Inc. EPS for the last quarter amounts to -0.45 USD, decreased -36.62 % YoY.

arrow icon

What changes have occurred in the market's expectations for Rocket Pharmaceuticals Inc (RCKT)'s fundamentals?

The market is revising Downward the revenue expectations for Rocket Pharmaceuticals, Inc. (RCKT) for FY2025, with the revenue forecasts being adjusted by -96.07% over the past three months. During the same period, the stock price has changed by 4.27%.
arrow icon

How many employees does Rocket Pharmaceuticals Inc (RCKT). have?

Rocket Pharmaceuticals Inc (RCKT) has 299 emplpoyees as of December 05 2025.

arrow icon

What is Rocket Pharmaceuticals Inc (RCKT) market cap?

Today RCKT has the market capitalization of 370.12M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free